EyeGate ekes out a tiny IPO to fund its R&D efforts

Damian Garde Massachusetts' EyeGate Pharmaceuticals picked up $ 10 million in an IPO do-over, raising cash to support its sole clinical candidate. FierceBiotech News

Ackman’s ‘wolf pack’ drove Allergan into foreign hands, former CEO says

Carly Helfand Former Allergan CEO David Pyott and activist investor Bill Ackman called each other plenty of things during last year's months-long Valeant-Allergan takeover battle. ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS